



(51) International Patent Classification:

A61K 31/385 (2006.01) *A61K 31/38* (2006.01)
A61K 31/554 (2006.01) *A61P 1/16* (2006.01)

(21) International Application Number:

PCT/US2012/062303

(22) International Filing Date:

26 October 2012 (26.10.2012)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/553,094 28 October 2011 (28.10.2011) US
61/607,487 6 March 2012 (06.03.2012) US

(71) Applicant: LUMENA PHARMACEUTICALS, INC.
[US/US]; 12531 High Bluff Drive, Suite 110, San Diego,
CA 92130 (US).(72) Inventors: GEDULIN, Bronislava; 14174 Half Moon
Bay Dr., Del Mar, CA 92014 (US). GREY, Michael; P. O.
Box 675614, Rancho Santa Fe, CA 92067 (US). O'DON-
NELL, Niall; 1046 Dewitt Ave., Encinitas, CA 92024
(US).(74) Agent: KIM, Joshua, E.; Wilson Sonsini Goodrich &
Rosati, 650 Page Mill Road, Palo Alto, CA 94304-1050
(US).(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY,

BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP,
KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI,
NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU,
RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ,
TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA,
ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— as to applicant's entitlement to apply for and be granted a
patent (Rule 4.17(ii))

Published:

— with international search report (Art. 21(3))
— before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments (Rule 48.2(h))


(54) Title: BILE ACID RECYCLING INHIBITORS FOR TREATMENT OF HYPERCHOLEMIA AND CHOLESTATIC LIVER
DISEASE

FIG.3

LUM001 decreases serum bile acids AUC 0-15 hr in study NB4-02-06-003
(measured on day 14; * $p < 0.05$, ** $p < 0.01$ compared to placebo)

(57) **Abstract:** Provided herein are methods of treating or ameliorating hypercholeemia or a cholestatic liver disease by administering to an individual in need thereof a therapeutically effective amount of an Apical Sodium- dependent Bile Acid Transporter Inhibitor (ASBTI) or a pharmaceutically acceptable salt thereof. Also provided are methods for treating or ameliorating a liver disease, decreasing the levels of serum bile acids or hepatic bile acids, treating or ameliorating pruritis, reducing liver enzymes, or reducing bilirubin comprising administering to an individual in need thereof a therapeutically effective amount of ASBTI or a pharmaceutically acceptable salt thereof.